Ewing Sarcoma clinical trials at UCSD
1 in progress, 0 open to eligible people
Sorry, not currently recruiting here
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
San Diego, California and other locations
Our lead scientists for Ewing Sarcoma research studies include Adam Burgoyne, MD.